Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.
Ontology highlight
ABSTRACT: Myelodysplastic syndrome (MDS) is a chronic hematologic disorder that frequently evolves to more aggressive stages and in some cases leads to acute myeloid leukemia (AML). MDS arises from mutations in hematopoietic stem cells (HSCs). Thus, to define optimal therapies, it is essential to understand molecular events driving HSC pathogenesis. In this study, we report that during evolution of MDS, malignant HSCs activate distinct cellular programs that render such cells susceptible to therapeutic intervention. Specifically, metabolic analyses of the MDS stem cell compartment show a profound activation of protein synthesis machinery and increased oxidative phosphorylation. Pharmacological targeting of protein synthesis and oxidative phosphorylation demonstrated potent and selective eradication
SUBMITTER: Stevens BM
PROVIDER: S-EPMC6135858 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA